These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34669544)

  • 1. The course of COVID-19 in patients with severe asthma receiving biological treatment.
    Tuncay G; Cakmak ME; Can Bostan O; Kaya SB; Damadoglu E; Karakaya G; Kalyoncu AF
    J Asthma; 2022 Nov; 59(11):2174-2180. PubMed ID: 34669544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and clinical course of COVID-19 in patients using omalizumab for chronic spontaneous urticaria and/or severe allergic asthma and using mepolizumab for severe eosinophilic asthma: A single center real life experience.
    Yıldız R; Demirel YS; Mungan VD; Aydın Ö; Sin BA; Ağca M; Bavbek S
    Tuberk Toraks; 2022 Sep; 70(3):231-241. PubMed ID: 36164947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.
    Papaioannou AI; Fouka E; Tzanakis N; Antoniou K; Samitas K; Zervas E; Kostikas K; Bartziokas K; Porpodis K; Papakosta D; Tzouvelekis A; Gerogianni I; Kotsiou O; Makris M; Rovina N; Vlachou G; Markatos M; Vittorakis S; Katsoulis K; Papanikolaou I; Afthinos A; Katsaounou P; Steiropoulos P; Latsios D; Dimakou K; Koukidou S; Hillas G; Tryfon S; Kallieri M; Georgopoulou A; Avarlis P; Bakakos P; Markopoulou K; Gaki E; Paspala A; Kyriakaki Z; Gourgoulianis KI; Papiris S; Loukides S
    J Allergy Clin Immunol Pract; 2022 Oct; 10(10):2588-2595. PubMed ID: 35752436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence.
    Adir Y; Humbert M; Saliba W
    J Allergy Clin Immunol; 2021 Aug; 148(2):361-367.e13. PubMed ID: 34144110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of biological therapy in children and adolescents with severe asthma during the COVID-19 pandemic: a case series.
    Votto M; Santi V; Bajeli M; De Filippo M; Deidda E; De Stefano E; Dianin F; Raviola C; Silvi C; Marseglia GL; Licari A
    Acta Biomed; 2022 Jun; 93(S3):e2022053. PubMed ID: 35666117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologicals decrease psychological distress, anxiety and depression in severe asthma, despite Covid-19 pandemic.
    Patella V; Pelaia C; Zunno R; Pelaia G
    Respir Med; 2022; 200():106916. PubMed ID: 35809428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric asthma control during the COVID-19 pandemic.
    Ferraro VA; Zamunaro A; Spaggiari S; Di Riso D; Zanconato S; Carraro S
    Immun Inflamm Dis; 2021 Jun; 9(2):561-568. PubMed ID: 33657264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of biologics in severe asthmatic patients with SARS-CoV-2 infection: A prospective study.
    Manti S; Giallongo A; Pecora G; Parisi GF; Papale M; Mulè E; Aloisio D; Rotolo N; Leonardi S
    Pediatr Pulmonol; 2023 Apr; 58(4):1085-1091. PubMed ID: 36593591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [COVID-19 and asthma].
    Louis R; Calmes D; Frix AN; Schleich F
    Rev Med Liege; 2020 Sup; 75(S1):130-132. PubMed ID: 33211435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COVID-19 in patients with severe asthma using biological agents.
    Aksu K; Demir Ş; Topel M; Yeşilkaya S; Ateş H; Koca Kalkan İ; Öncül A; Çuhadar Erçelebi D; Türkyılmaz S
    Tuberk Toraks; 2021 Sep; 69(3):433-436. PubMed ID: 34581170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case study: A Combination of Mepolizumab and Omaluzimab injections for severe asthma.
    Dedaj R; Unsel L
    J Asthma; 2019 May; 56(5):473-474. PubMed ID: 29733738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison.
    Cockle SM; Stynes G; Gunsoy NB; Parks D; Alfonso-Cristancho R; Wex J; Bradford ES; Albers FC; Willson J
    Respir Med; 2017 Feb; 123():140-148. PubMed ID: 28137490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)
    Klimek L; Pfaar O; Worm M; Eiwegger T; Hagemann J; Ollert M; Untersmayr E; Hoffmann-Sommergruber K; Vultaggio A; Agache I; Bavbek S; Bossios A; Casper I; Chan S; Chatzipetrou A; Vogelberg C; Firinu D; Kauppi P; Kolios A; Kothari A; Matucci A; Palomares O; Szépfalusi Z; Pohl W; Hötzenecker W; Rosenkranz AR; Bergmann KC; Bieber T; Buhl R; Buters J; Darsow U; Keil T; Kleine-Tebbe J; Lau S; Maurer M; Merk H; Mösges R; Saloga J; Staubach P; Jappe U; Rabe KF; Rabe U; Vogelmeier C; Biedermann T; Jung K; Schlenter W; Ring J; Chaker A; Wehrmann W; Becker S; Freudelsperger L; Mülleneisen N; Nemat K; Czech W; Wrede H; Brehler R; Fuchs T; Tomazic PV; Aberer W; Fink-Wagner AH; Horak F; Wöhrl S; Niederberger-Leppin V; Pali-Schöll I; Pohl W; Roller-Wirnsberger R; Spranger O; Valenta R; Akdis M; Matricardi PM; Spertini F; Khaltaev N; Michel JP; Nicod L; Schmid-Grendelmeier P; Idzko M; Hamelmann E; Jakob T; Werfel T; Wagenmann M; Taube C; Jensen-Jarolim E; Korn S; Hentges F; Schwarze J; O Mahony L; Knol EF; Del Giacco S; Chivato Pérez T; Bousquet J; Bedbrook A; Zuberbier T; Akdis C; Jutel M
    Allergol Select; 2020; 4():53-68. PubMed ID: 32915172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
    Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
    Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.